In the MMR-deficient model (PDX58), one of the established lineages was enriched for a subclone with hotspot KRAS and TP53 mutations and over 50% private mutations, suggesting that this subclone had diverged early on in the tumor evolution. The gene discussed is KRAS; the disease is neoplasm.